Novartis AG with ticker code (NVS) have now 4 analysts in total covering the stock. The consensus rating is pointing to ‘Buy’. The range between the high target price and low target price is between 113.5 and 103 calculating the average target price we see $107.13. Given that the stocks previous close was at $98.02 this would indicate that there is a potential upside of 9.3%. It’s also worth noting that there is a 50 day moving average of $88.22 and the 200 moving average now moves to $85.55. The company has a market capitalization of $209,936m. Find out more information at: https://www.novartis.com
The potential market cap would be $229,448m based on the market consensus.
Novartis AG researches, develops, manufactures, and markets healthcare products in Switzerland and internationally. The company operates through two segments: Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and physicians. It also provides cardiovascular, ophthalmology, neuroscience, immunology, hematology, and solid tumor products. The Sandoz segment develops, manufactures, and markets finished dosage forms of small molecule pharmaceuticals to third parties. It also provides protein- or other biotechnology-based productsluding biosimilars; and biotechnology manufacturing services; and anti-infectives, such as active pharmaceutical ingredients and intermediates primarily antibiotics. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.
The company has a dividend yield of 3.57% with the ex dividend date set at 9-3-2023 (DMY).
Other points of data to note are a P/E ratio of 31.1, revenue per share of 23.76 and a 6.45% return on assets.
